Article Dans Une Revue ChemMedChem Année : 2021

Drimane derivatives as the first examples of covalent BH3-mimetics that target MCL-1

Sandy Desrat

Résumé

Drimane sesquiterpenoid dialdehydes are natural compounds with antiproliferative properties. Nevertheless, their mode of action has not yet been discovered. In this publication, we have demonstrated that various drimanes are potent inhibitors of MCL-1 and BCL-xL, two proteins of the BCL-2 family that are overexpressed in various cancers, including lymphoid malignancies. Subtle changes in their structure significantly modified their activity on the target proteins. The two most active compounds are MCL-1 selective and bind in the BH3 binding groove of the protein. Complementary studies, by NMR and mass spectrometry analyses but also synthesis showed that they are covalent inhibitors of MCL-1, via the formation of a pyrrole adduct. In addition, cytotoxic assays revealed that these two compounds show a cytotoxic selectivity for BL2, a MCL-1/BCL-xL dependent cell line and induce apoptosis.

Fichier principal
Vignette du fichier
Roussi et al. Drimane derivatives as the first examples of covalent BH3.pdf (2.34 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-03279424 , version 1 (06-07-2021)

Licence

Identifiants

Citer

Florian Daressy, Florian Malard, Line Seguy, Vincent Guérineau, Cécile Apel, et al.. Drimane derivatives as the first examples of covalent BH3-mimetics that target MCL-1. ChemMedChem, 2021, 16 (11), pp.1789-1798. ⟨10.1002/cmdc.202100011⟩. ⟨hal-03279424⟩
251 Consultations
326 Téléchargements

Altmetric

Partager

  • More